These findings underline the importance of using immunohistochemical markers to assess tumor behavior and predict survival, highlighting the role of Ki67 in proliferative assessment, albeit with limited prognostic accuracy in clinical settings [125]. This evidence concerns the gene MKI67 and neoplasm.